Finance

Senarai
Sebab LONA menurun 3.99%?
Terokai Dengan Lebih Terperinci
LONA:NASDAQ
LeonaBio Inc
USD 2.65
-3.99%
(-0.11) 1H
USD 2.55
-3.77% (-0.10)
Selepas waktu pejabat
Ditutup: 18 Nov, 4:00:01 PTG GMT-5  ·   USD
Semua simbol
SimbolHargaPerubahan% Perubahan
Menjana cerapan popular untuk LONA...
Buka
USD 2.77
Tinggi
USD 3.05
Rendah
USD 2.51
Permodalan Pasaran
34.65J
Purata volum
77.64K
Volum
44.50K
tgi 52 mgu
USD 14.19
rdh 52 mgu
USD 2.21
EPS
-USD 19.72
Beta
1.91
Syer tertunggak
13.08J
Bilangan pekerja
19
Buka
USD 2.77
Tinggi
USD 3.05
Rendah
USD 2.51
Permodalan Pasaran
34.65J
Purata volum
77.64K
Volum
44.50K
tgi 52 mgu
USD 14.19
rdh 52 mgu
USD 2.21
EPS
-USD 19.72
Beta
1.91
Syer tertunggak
13.08J
Bilangan pekerja
19
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors. Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Perihal LeonaBio Inc
CEO-
Pekerja19
Diasaskan2011
Ibu pejabatBothell, Washington, Amerika Syarikat
SektorHealth Care
Industri-
Laman webleonabio.com
Rating penganalisis
Berdasarkan 3 penganalisis yang memberikan rating saham kepada LONA dalam tempoh 3 bulan yang lalu
Belian kuat
Beli
3
Pegang
0
Jual
0
Ramalan 12 bulan
Berdasarkan 3 penganalisis Wall Street yang menawarkan sasaran harga 12 bulan untuk LONA dalam tempoh 3 bulan yang lalu.
Tertinggi
Semasa USD 2.65
USD 20.00 (+654.72%)
Purata
USD 16.00 (+503.77%)
Terendah
USD 12.00 (+352.83%)
Penganalisis
Syor
Tindakan
Sasaran harga
Diunjurkan
Tarikh
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
USD 12.00
+352.8%
11/18/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
USD 20.00
+654.7%
11/18/2026
Jason Butler
Citizens JMP
Buy
Maintained
USD 16.00
+503.8%
11/17/2026
Eric Schmidt FCA
Cantor Fitzgerald
Buy
Reiterated
-
-
04/07/2026
Laporan sebelumnyaSemua nilai dalam USD
Loading Previous Earnings...
Hasil
Pendapatan bersih
Semua nilai dalam USD
Sep 2025
Dis 2025
Mac 2026
Jun 2026
Hasil
-
-
-
-
Kos barangan yang dijual
-
-
-
-
Kos hasil
-
-
-
-
Perbelanjaan penyelidikan dan pembangunan
2.82J
6.71J
11.26J
12.70J
Jumlah perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Perbelanjaan jualan, am dan pentadbiran
4.05J
3.76J
6.88J
6.58J
Belanja kendalian
6.87J
10.48J
18.14J
19.28J
Jumlah belanja kendalian
6.87J
10.48J
18.14J
19.28J
Pendapatan kendalian
-6.87J
-10.48J
-18.14J
-19.28J
Pendapatan bukan kendalian lain
263.00K
-4.39J
-15.06J
271.00K
EBT termasuk item luar biasa
-6.61J
-82.89J
-32.95J
-19.01J
EBT tidak termasuk item luar biasa
-6.61J
-14.87J
-33.21J
-19.01J
Belanja cukai pendapatan
-
-
-
-
Kadar cukai berkesan
-
-
-
-
Belanja kendalian lain
-
-
-
-
Pendapatan bersih
-6.61J
-82.89J
-32.95J
-19.01J
Margin untung bersih
-
-
-
-
Perolehan bagi setiap syer
-
-
-
-
Pendapatan faedah dan pelaburan
-
-
-
-
Belanja faedah
-
-
-
-
Belanja faedah bersih
-
-
-
-
Caj susut nilai dan pelunasan
-
-
-
-
EBITDA
-6.63J
-10.23J
-17.91J
-19.05J
Keuntungan atau kerugian daripada jualan aset
-
-
-
-
Transaksi orang dalam
Data transaksi orang dalam diperoleh daripada sumber pihak ketiga. Ketahui lebih lanjut
Orang dalam
Jawatan
Jenis
Tarikh
Saham
Jumlah
Halaman 1
Acara akan datang
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut
BantuanHantar maklum balasPrivasiSyaratPenafian
Apl Google